

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

Product Datasheet

Human EPO protein, His tag (active), Unconjugated GTX00251-PRO

Article Name	Human EPO protein, His tag (active), Unconjugated
Biozol Catalog Number	GTX00251-PRO
Supplier Catalog Number	GTX00251-pro
Alternative Catalog Number	GTX00251-PRO-10
Manufacturer	GeneTex
Category	Proteine/Peptide
Application	FA
Species Reactivity	Human
Conjugation	Unconjugated
NCBI	2056
UniProt	P01588
Buffer	Reconstitute with 10mM PBS (pH7.4) to 0.1-1.0mg/ml. Do not vortex. Lyophilized from PBS (pH7.4), 0.01% SKL, 1mM DTT, 5% Trehalose, ProClin 300.
Expression System	HEK293 cells
Form	Lyophilized powder
Sequence	N-terminal His-Tag, Ala28~Arg193 (NP_000790.2)

Application Notes

Erythropoietin (EPO), also known as hematopoietin or hemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia. Erythropoietin is an essential hormone for red blood cell production. Its primary effect on red blood cell progenitors and precursors (which are found in the bone marrow in humans) by promoting their survival through protecting these cells from apoptosis, or cell death. EPO is the primary erythropoietic factor that cooperates with various other growth factors involved in the development of erythroid lineage from multipotent progenitors. Besides, Erythropoietin Receptor (EPOR) has been identified as an interactor of EPO, thus a binding ELISA assay was conducted to detect the interaction of recombinant human EPO and recombinant human EPOR. Briefly, EPO were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 µl were then transferred to EPOR-coated microtiter wells and incubated for 2h at 37C. Wells were washed with PBST and incubated for 1h with anti-EPO pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37C. Finally, add 50 µl stop solution to the wells and read at 450nm immediately. The binding activity of EPO and EPOR was in a dose dependent manner. To test the effect of EPO on cell proliferation, TF-1 cells were seeded into triplicate wells of 96-well plates at a density of 5000 cells/well with 1% serum standard RPMI-1640 including various concentrations of recombinant human EPO. After incubated for 72h, cells were observed by inverted microscope and cell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10 µl of CCK-8 solution was added to each well of the plate, then the absorbance at 450nm was measured using a microplate reader after incubating the plate for 1-4 hours at 37C. Proliferation of TF-1 cells after incubation with EPO for 72h observed by inverted microscope. Cell viability was assessed by CCK-8 (Cell Counting Kit-8) assay after incubation with recombinant EPO for 72h, and EPO significantly increased cell viability of TF-1 cells.